176 related articles for article (PubMed ID: 35100339)
1. Langerhans dendritic cell vaccine bearing mRNA-encoded tumor antigens induces antimyeloma immunity after autotransplant.
Chung DJ; Sharma S; Rangesa M; DeWolf S; Elhanati Y; Perica K; Young JW
Blood Adv; 2022 Mar; 6(5):1547-1558. PubMed ID: 35100339
[TBL] [Abstract][Full Text] [Related]
2. Langerhans-type dendritic cells electroporated with TRP-2 mRNA stimulate cellular immunity against melanoma: Results of a phase I vaccine trial.
Chung DJ; Carvajal RD; Postow MA; Sharma S; Pronschinske KB; Shyer JA; Singh-Kandah S; Dickson MA; D'Angelo SP; Wolchok JD; Young JW
Oncoimmunology; 2017; 7(1):e1372081. PubMed ID: 29296525
[No Abstract] [Full Text] [Related]
3. Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients.
Rosenblatt J; Avivi I; Vasir B; Uhl L; Munshi NC; Katz T; Dey BR; Somaiya P; Mills H; Campigotto F; Weller E; Joyce R; Levine JD; Tzachanis D; Richardson P; Laubach J; Raje N; Boussiotis V; Yuan YE; Bisharat L; Held V; Rowe J; Anderson K; Kufe D; Avigan D
Clin Cancer Res; 2013 Jul; 19(13):3640-8. PubMed ID: 23685836
[TBL] [Abstract][Full Text] [Related]
4. Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells.
Rapoport AP; Aqui NA; Stadtmauer EA; Vogl DT; Xu YY; Kalos M; Cai L; Fang HB; Weiss BM; Badros A; Yanovich S; Akpek G; Tsao P; Cross A; Mann D; Philip S; Kerr N; Brennan A; Zheng Z; Ruehle K; Milliron T; Strome SE; Salazar AM; Levine BL; June CH
Clin Cancer Res; 2014 Mar; 20(5):1355-65. PubMed ID: 24520093
[TBL] [Abstract][Full Text] [Related]
5. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.
Gay F; Musto P; Rota-Scalabrini D; Bertamini L; Belotti A; Galli M; Offidani M; Zamagni E; Ledda A; Grasso M; Ballanti S; Spadano A; Cea M; Patriarca F; D'Agostino M; Capra A; Giuliani N; de Fabritiis P; Aquino S; Palmas A; Gamberi B; Zambello R; Petrucci MT; Corradini P; Cavo M; Boccadoro M
Lancet Oncol; 2021 Dec; 22(12):1705-1720. PubMed ID: 34774221
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma.
Wilgenhof S; Van Nuffel AM; Corthals J; Heirman C; Tuyaerts S; Benteyn D; De Coninck A; Van Riet I; Verfaillie G; Vandeloo J; Bonehill A; Thielemans K; Neyns B
J Immunother; 2011 Jun; 34(5):448-56. PubMed ID: 21577140
[TBL] [Abstract][Full Text] [Related]
8. T-cell Exhaustion in Multiple Myeloma Relapse after Autotransplant: Optimal Timing of Immunotherapy.
Chung DJ; Pronschinske KB; Shyer JA; Sharma S; Leung S; Curran SA; Lesokhin AM; Devlin SM; Giralt SA; Young JW
Cancer Immunol Res; 2016 Jan; 4(1):61-71. PubMed ID: 26464015
[TBL] [Abstract][Full Text] [Related]
9. Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401.
Chung DJ; Shah N; Wu J; Logan B; Bisharat L; Callander N; Cheloni G; Anderson K; Chodon T; Dhakal B; Devine S; Somaiya Dutt P; Efebera Y; Geller N; Ghiasuddin H; Hematti P; Holmberg L; Howard A; Johnson B; Karagkouni D; Lazarus HM; Malek E; McCarthy P; McKenna D; Mendizabal A; Nooka A; Munshi N; O'Donnell L; Rapoport AP; Reese J; Rosenblatt J; Soiffer R; Stroopinsky D; Uhl L; Vlachos IS; Waller EK; Young JW; Pasquini MC; Avigan D
Clin Cancer Res; 2023 Dec; 29(23):4784-4796. PubMed ID: 37463058
[TBL] [Abstract][Full Text] [Related]
10. Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma.
Rapoport AP; Aqui NA; Stadtmauer EA; Vogl DT; Fang HB; Cai L; Janofsky S; Chew A; Storek J; Akpek G; Badros A; Yanovich S; Tan MT; Veloso E; Pasetti MF; Cross A; Philip S; Murphy H; Bhagat R; Zheng Z; Milliron T; Cotte J; Cannon A; Levine BL; Vonderheide RH; June CH
Blood; 2011 Jan; 117(3):788-97. PubMed ID: 21030558
[TBL] [Abstract][Full Text] [Related]
11. Lenalidomide consolidation and maintenance therapy after autologous stem cell transplant for multiple myeloma induces persistent changes in T-cell homeostasis.
Clave E; Douay C; Coman T; Busson M; Bompoint C; Moins-Teisserenc H; Glauzy S; Carmagnat M; Gorin NC; Toubert A; Garderet L
Leuk Lymphoma; 2014 Aug; 55(8):1788-95. PubMed ID: 24237448
[TBL] [Abstract][Full Text] [Related]
12. TIGIT inhibition and lenalidomide synergistically promote antimyeloma immune responses after stem cell transplantation in mice.
Minnie SA; Waltner OG; Ensbey KS; Olver SD; Collinge AD; Sester DP; Schmidt CR; Legg SR; Takahashi S; Nemychenkov NS; Sekiguchi T; Driessens G; Zhang P; Koyama M; Spencer A; Holmberg LA; Furlan SN; Varelias A; Hill GR
J Clin Invest; 2023 Feb; 133(4):. PubMed ID: 36512425
[TBL] [Abstract][Full Text] [Related]
13. Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial.
Manasanch EE; Shah JJ; Lee HC; Weber DM; Thomas SK; Amini B; Feng L; Berkova Z; Hildebrandt M; Orlowski RZ
Lancet Haematol; 2018 Dec; 5(12):e628-e640. PubMed ID: 30501870
[TBL] [Abstract][Full Text] [Related]
14. Survivin Dendritic Cell Vaccine Safely Induces Immune Responses and Is Associated with Durable Disease Control after Autologous Transplant in Patients with Myeloma.
Freeman CL; Atkins R; Varadarajan I; Menges M; Edelman J; Baz R; Brayer J; Castaneda Puglianini O; Ochoa-Bayona JL; Nishihori T; Shain KH; Shah B; Chen DT; Kelley L; Coppola D; Alsina M; Antonia S; Anasetti C; Locke FL
Clin Cancer Res; 2023 Nov; 29(22):4575-4585. PubMed ID: 37735756
[TBL] [Abstract][Full Text] [Related]
15. A randomized phase 2 trial of idiotype vaccination and adoptive autologous T-cell transfer in patients with multiple myeloma.
Qazilbash MH; Saini NY; Cha SC; Wang Z; Stadtmauer EA; Baladandayuthapani V; Lin H; Tross B; Honhar M; Rao SS; Kim K; Popescu M; Szymura S; Zhang T; Anderson A; Bashir Q; Shpall EJ; Orlowski RZ; Levine BL; Kerr N; Garfall A; Cohen A; Vogl DT; Dengel K; June CH; Champlin R; Kwak LW
Blood; 2022 Mar; 139(9):1289-1301. PubMed ID: 34521108
[TBL] [Abstract][Full Text] [Related]
16. TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma.
De Keersmaecker B; Claerhout S; Carrasco J; Bar I; Corthals J; Wilgenhof S; Neyns B; Thielemans K
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32114500
[TBL] [Abstract][Full Text] [Related]
17. Lenalidomide and Vorinostat Maintenance after Autologous Transplantation in Multiple Myeloma: Long- Term Follow-Up.
Sharma N; Chen DT; Zhao Q; Williams NY; Rosko A; Benson DM; Chaudhry M; Bumma N; Khan A; Devarakonda S; Hofmeister CC; Sborov D; Efebera YA
Biol Blood Marrow Transplant; 2020 Jan; 26(1):44-49. PubMed ID: 31518644
[TBL] [Abstract][Full Text] [Related]
18. Revaccination after Autologous Hematopoietic Stem Cell Transplantation Is Safe and Effective in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance.
Palazzo M; Shah GL; Copelan O; Seier K; Devlin SM; Maloy M; Kenny S; Hassoun H; Korde NS; Lendvai N; Lesokhin AM; Mailankody S; Chung DJ; Koehne G; Landgren CO; Landau H; Giralt SA; Perales MA
Biol Blood Marrow Transplant; 2018 Apr; 24(4):871-876. PubMed ID: 29288818
[TBL] [Abstract][Full Text] [Related]
19. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial.
Kumar SK; Jacobus SJ; Cohen AD; Weiss M; Callander N; Singh AK; Parker TL; Menter A; Yang X; Parsons B; Kumar P; Kapoor P; Rosenberg A; Zonder JA; Faber E; Lonial S; Anderson KC; Richardson PG; Orlowski RZ; Wagner LI; Rajkumar SV
Lancet Oncol; 2020 Oct; 21(10):1317-1330. PubMed ID: 32866432
[TBL] [Abstract][Full Text] [Related]
20. Autologous Lymphocyte Infusion Supports Tumor Antigen Vaccine-Induced Immunity in Autologous Stem Cell Transplant for Multiple Myeloma.
Cohen AD; Lendvai N; Nataraj S; Imai N; Jungbluth AA; Tsakos I; Rahman A; Mei AH; Singh H; Zarychta K; Kim-Schulze S; Park A; Venhaus R; Alpaugh K; Gnjatic S; Cho HJ
Cancer Immunol Res; 2019 Apr; 7(4):658-669. PubMed ID: 30745365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
